Skip to main content
. Author manuscript; available in PMC: 2019 Jan 26.
Published in final edited form as: ACS Nano. 2016 Dec 27;11(1):395–406. doi: 10.1021/acsnano.6b06104

Figure 1.

Figure 1.

Schematic of dissolvable MNs mediating local delivery of peptide CGRP antagonist to produce analgesia for the treatment of neuropathic pain. (a) Peptide CGRP antagonist mitigates neuropathic pain by selectively blocking CGRP receptors and inhibiting CGRP signaling. (b) Dissolvable MNs transdermally delivered CGRP antagonist peptide directly to the local neuropathic pain area in a painless manner.